Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano’s Optical Genome Mapping Technology Can Diagnose Significantly More Patients Than Standard of Care Methods Alone

Publication from UCSF shows Bionano’s optical genome mapping technology can detect pathogenic variants missed by whole exome sequencing and by chromosomal microarray in patients with rare genetic disorders and may contribute to more patients receiving definitive molecular diagnoses

November 05, 2020 08:00 ET | Source: Bionano Genomics
SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study led by scientists and clinicians from the Institute for Human Genetics and the Benioff Children’s Hospital at the University of California, San Francisco (UCSF) that evaluated the ability of Bionano’s optical genome mapping technology and another genome analysis method to diagnose children with genetic conditions who previously went undiagnosed by the standard of care methods alone. Of the 50 children in the study, the optical genome mapping results were sufficient to definitively diagnose 6 patients (or 12%) and, for another 10 patients (or 20%), the Bionano data revealed candidate pathogenic variants. Upon further analysis, it is expected that an additional 3 patients could be diagnosed with the Bionano data, bringing the total of definitively diagnosed patients to 9 (or 18%).

Erik Holmlin, Ph.D., CEO of Bionano Genomics commented, “Increasing the number of patients who receive a definitive molecular diagnosis is the driving force behind much of the development of new diagnostic technologies. Every major change in medical guidelines connected to introducing novel methods has been driven by the ability of new methods to diagnose more patients than the previously existing standard of care. This study by the UCSF team shows that Bionano’s optical genome mapping can potentially bring another such leap to the clinic by diagnosing many more patients than what existing chromosomal microarray (CMA) and whole exome sequencing (WES) can. Several studies released this year have shown that Saphyr can detect all clinically relevant variants identified by karyotyping, microarray and FISH in both leukemias and genetic disease cases. This UCSF study now shows in the largest cohort analyzed to date that Bionano’s optical genome mapping diagnoses more patients than the traditional methods. We believe the increase in diagnosis over conventional methods can be a significant factor in Saphyr gaining widespread adoption as a clinical tool for genetic disease diagnosis and next-generation cytogenomics.”

As described in the publication, the UCSF team performed full genome analysis by combining optical genome mapping with Bionano technology and linked-read sequencing on 50 undiagnosed patients with a variety of rare genetic diseases and their parents to determine if this full genome analysis method could help solve cases that had not been diagnosed with previous testing. Of the 50 cases, 42 were previously analyzed by CMA, the first tier medical test for genetic disease cases, and 23 had previously been analyzed with commercial trio whole exome sequencing, and no pathogenic or likely pathogenic variants were identified by these methods.

Bionano’s optical genome mapping technology identified a number of pathogenic variants unidentified by CMA and undetectable by WES, including duplications and deletions that were too small to be identified by CMA, or occurred in regions of the genome not typically covered by CMA or WES. Of the additional 7 patients with variations considered to be candidates for pathogenic variants, the findings included deletions, duplications, and inversions. Before concluding that these variants are sufficient to diagnose the patients, further analysis is required since these variants had not previously been reported in patients with similar disease.

Adding in the .52s.. lets go!

I don’t think it will go lower than 6. My average is just above 6, so not worried I’ll be a big bag holder.. I think Monday is another positive day anyway..

This news should get JE back over pre split values.. I’m thinking this gets over $9 quickly, and maybe in the teens next week!

Very cleaver.. let’s get this back over .10 tomorrow

I have TDA and received mine afew days ago. 7sp993104

It says $8.10 now, looks like we going up! but I probably bought your shares yesterday at .361. Let’s hope this injection will blow JE way past $10 this week.

Just think we still have power hour.. this is pretty much when the shorts nail out because they see the volume and realize this isn’t going down to .40 below again.. I think after hours it breaks out...

Adding A lot at .50

Looks like it’s ready to start the move back over .40. Just in time added at .30

Strong day.. I’ll be buying more under. .12 weeee let’s get over that quick

Looking good.. let’s get this over .60 and we fly to $1:)

Nice news, this should help get BNGO back over that $1 soon....

Chris Stewart joins Bionano from Tesla where he headed up the ultracapacitor business unit. Over his career, he has served in a number of executive roles in private and public commercial stage companies including as controller, V.P. of Finance and CFO. Chris’s breadth of operational finance experience will be a key to Bionano’s continued global expansion.

SAN DIEGO, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Christopher Stewart will join Bionano as its Chief Financial Officer, effective September 1, 2020. Chris has a breadth of experience in finance, accounting, and strategic planning for commercial-stage operating businesses. He has overseen financial management for technology companies with both product and service models. Chris is also experienced in leading various business functions, including finance, IT, human resources, and investor relations, and has demonstrated leadership through major financing events and acquisitions. Additionally, he has in-depth operational knowledge of the semiconductor industry, which utilizes similar manufacturing processes and types of manufacturing partners that are used to make Saphyr chips. Scaling Saphyr consumable production and use is a cornerstone of Bionano’s growth plans, and improving the margins of Saphyr consumables is a key to Bionano’s path to profitability. We believe Chris’ experience in scaling revenues in high-growth tech companies and the semiconductor industry will contribute greatly to his service to Bionano as its Chief Financial Officer, and that this expertise will be instrumental to executing our business plan, including global expansion of our Saphyr business and service offering.

Chris joins Bionano most recently from Tesla, where he served as Head of the Maxwell Ultracapacitors business unit after Maxwell Technology was acquired by Tesla. Prior to this acquisition, he served as Vice President of Finance & Information Technology at Maxwell Technologies, a then publicly traded company. Prior to Maxwell Technologies, he served as Vice President, Finance at Entropic Communications, a publicly traded company and a leader in semiconductor solutions and as Chief Financial Officer of V-ENABLE (now xAD), a leader in targeted mobile advertising. Chris has demonstrated extensive mergers and acquisition experience as well as experience with public finance and financial reporting.

Erik Holmlin, PhD, CEO of Bionano Genomics commented: “We are thrilled to have Chris Stewart join us as Chief Financial Officer. He is a hands-on finance executive with over 20 years of experience at companies ranging from startups to large public companies. Importantly, he is familiar with both products and services and has a very strong finance and operations background. He arrives at a perfect time, as we just completed our acquisition of Lineagen and brought Alka Chaubey on board as our Chief Medical Officer, setting us up for the next phase in Bionano’s growth. His leadership in scaling high-growth tech companies will be invaluable as Bionano embarks on our next phase of global expansion of our Saphyr, consumables and services business and as we strive to make Saphyr the future of digital cytogenetics.”

Very nice, I’ll be adding some more.. let’s get past 6, 7,8 hey.

Please add the link, that would be nice

Thanks.. sounds good, but how fast can we turn around and sell the extra rights? I heard something like that also on another board. However I talked with ameritrade on Friday and they still didn’t have any idea and info about the rights.

Anyone have any idea on when we can use the new stock options shareholders received last week to buy more JE? And what price?

It’s going to be a good week here with JE:)

$JE
offering of ~2.45 Canadian or around 1.80US!

Buy this sucker, it’s under .60 again! Don’t let the shorts get out cheap... this should be over $1.. only a matter of time..

Weeeeeeee:) lol

Volume spike today after hours, maybe tomorrow it’s going to get more.... Let’s hope it breaks back over .56 early then $1 is around the corner..

Looks like this news should push ZOM back into the .30’s tomorrow:)

https://todaysfive.com/bionano-genomics-press-release

UPDATE – 1:53 PM: CEO Robert Erik Holmlin has postponed the expected press release until next Monday


Good morning and happy Tuesday! Stock of the day? Bionano Genomics (BNGO), the small San Diego life sciences company was given approval to their new patent this morning. (Source)

News of the patent caused an early morning jump of over 9%, this is expected to continue to rise through the afternoon once news of the patents release is officially announced. Bionano Genomics press release expected today.

Very interesting to see Bionana Genomics drop a patent like this AFTER market opening. Either way, since the news of the patent came out, volume for BNGO has gone up over 4 million and is steadily climbing.

Bionano Genomics press release
For about 3 months Bionano Genomics has been a stock mostly controlled by day traders, as is the case for many company stocks since the start of the pandemic. But with the introduction of this new patent, there is a lot of speculation that long-term investors will be willing to buy in again. It’s worth remembering that 3 months ago, before the pandemic, Bionano Genomics was trading at over $1 per share.

On top of that – Bionano Genomics CEO is not over-zealous. He is projecting a conservative revenue gain for Q1 given the circumstances of the pandemic. We have seen in the past weeks investors turn away from companies that predict unrealistic revenue gains. Potential long term buyers will appreciate the realistic expectations.

CEO Robert Erik Holmlin has announced there is a Bionano Genomics press release scheduled for 3:00 PM Tuesday, Pacific Time.

Why is this trading at 1am PST? I didn’t think pre trading was that early? Lol

It was a-little ugly, but maybe some traders maybe took advantage of it. trying to buy low and sell higher.. I personally sold afew times today, but also bought acouple times 2:)

Added again today at .30:) maybe add more on Monday to help get back into the .40+ easy to see this will bounce as I can see money flow wants back in. Only traders trying to make alittle in the way back up 2.

Added a little myself:)!

This is the Right stock and right time! This going over $1 sooner than later. Loading my ship...

That’s why I was adding at ton again under .60:). This is going back over a dollar this week... IMHo

Adding 1.25 just about bottom.?.

Maybe back over $1 also:)

Yes it is, and is now Bouncing back alittle.

Looking strong, going over $2

Nice call! :)

Added some PRTY, wee let the party start..

Added some at 2.11, let see if $2.. hoping that’s bottom...

It’s good to be upgraded!:)

https://www.otcmarkets.com/stock/OTCM/news/OTC-Markets-Group-Announces-Lists-of-Compliance-Downgrades-and-Caveat-Emptor-Designations-for-the-Month-of-November?id=248434.

Added some at 1.80 today.. let’s get back over 2$:)